Vimarsana
Biggest News Aggregation in the World

Johnr Su News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Johnr Su. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Johnr Su Today - Breaking & Trending Today

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022 - Vimarsana News

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022

This report describes safety monitoring after a Pfizer-BioNTech booster vaccination among children and adolescents aged 12-17 years.

Source: cdc.gov
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022 - Vimarsana News

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022

This report describes safety monitoring after a Pfizer-BioNTech booster vaccination among children and adolescents aged 12-17 years.

Source: cdc.gov
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022 - Vimarsana News

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022

This report describes how local and systemic reactions and myocarditis are less frequent after a homologous COVID-19 booster dose.

Source: cdc.gov
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - Vimarsana News

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine

VAERS received and processed ††† 13,725 adverse event reports for Janssen COVID-19 vaccine recipients; median age was 42 years, and 66% were women (Table 1). Among these VAERS reports, 13,294 (97%) were classified as nonserious, and 343 (3%) were classified as serious, including three reports of non-CVST TTS (no deaths). Two of the TTS cases occurred among women aged 30–39 years and one in a woman aged 50–59 years. Each of these women had evidence of large-vessel thrombosis and thrombocytopenia (Table 2). As of April 25, 14 CVST cases had been confirmed ( 8), for a total of 17 TTS c...

Source: cdc.gov